The hottest girl at the dance right now may be Juno, and she hasn't partnered with a BP/BB either. Juno's only partnerships are with its research collaborators, Fred Hutchinson Cancer Research Center of Seattle, the Seattle Children’s Research Institute, and Memorial Sloan-Kettering Cancer Center in New York.
Those parties have been promised lucrative rewards for letting Juno use their technologies, including “success payments” based on Juno's stock price (Sangamo hasn't incurred such obligations). But so far, Juno shows no sign of partnering for manufacturing, marketing, or distribution.
The market for advanced cancer therapies is quite limited. There are only a few dozen top oncology medical centers that service the needs of their respective regions. It wouldn't take a large sales force to reach them or a large team to manage the clinical trials.
If Sangamo can succeed in developing an "off the shelf" version of the technology, then manufacturing will be centralized, greatly simplifying the logistics of treatment and distribution, compared to the autologous model that Juno is using.
So the payoff might be better going solo on this one. If EL does make a deal, I hope he holds out for a great one, perhaps with benefits that go beyond this program.